Nomenclature for Kidney Function and Disease: Executive Summary and Glossary From a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference

Abstract

has received research support from AstraZeneca, the National Institute of Diabetes and Digestive and Kidney Diseases, and the National Kidney Foundation; Kai-Uwe Eckardt has received consultancy fees from Akebia, Bayer, and Genzyme, speaker honoraria from Bayer and Vifor, and research support from Amgen, AstraZeneca, Bayer, Fresenius Medical Care, and Genzyme; Nijsje M. Dorman has equity ownership/ stock options from Eli Lilly & Co; Michel Jadoul has received consultancy fees from Astellas, AstraZeneca, GSK, MSD, and Vifor Fresenius Medical Care Renal Pharma, speaker honoraria from AbbVie, Amgen, Menarini, MSD, and Vifor Fresenius Medical Care Renal Pharma, travel support from Amgen, and research support from Alexion, Amgen, Janssen-Cilag, Otsuka, and Roche; and Wolfgang C. Winkelmayer has received consultancy fees from Akebia, AMAG, Amgen, AstraZeneca, Bayer, Daiichi-Sankyo, Relypsa, and ZS Pharma, speaker honoraria from FibroGen, and research support from the National Institutes of Health. The remaining authors disclose no conflicts. This article is being published in Kidney International Reports and reprinted concurrently in several journals. The articles cover identical concepts and wording but vary in minor stylistic and spelling changes, detail, and length of manuscript, in keeping with each journal's style. Any of these versions may be used in citing this article. Excerpts are adapted with permission of Kidney Disease: Improving Global Outcomes (KDIGO) and the International Society of Nephrology.

Alterations in symptoms and health‐related quality of life as kidney function deteriorates: A cross‐sectional study

“…Depending on the level of kidney function, CKD is classified into five grades, G1–G5 (G3 is sub‐divided into G3a and G3b). The final grade (G5) was previously called end‐stage kidney disease but is now termed kidney failure (Levey et al, 2020). Once kidney failure is reached, collaborative decisions between individuals, family and the multidisciplinary kidney team are made about whether to commence kidney replacement therapy (either haemodialysis [HD], peritoneal dialysis [PD] or kidney transplantation) or to receive conservative (supportive) care (Webster et al, 2017).…”

The incidence of and risk factors for late presentation of childhood chronic kidney disease: A systematic review and meta-analysis

“…A descriptive analysis was undertaken for included studies according to late presentation definition used. The terminology contained within this report aligns with recommendations from Kidney Disease Improving Global Outcomes (KDIGO) consensus conference on nomenclature for kidney function and disease [16], although reference to study-specific terminology is made. For studies containing population data, the annual incidence of late presentation was calculated per million of the age-related population (pmarp).…”

Antimicrobial Dosing in Specific Populations and Novel Clinical Methodologies: Kidney Function

“…The current review explores the uncertainties associated with kidney function estimation and novel clinical methodologies to improve antibiotic dosing in this specific population of patients with abnormal kidney function and augmentation. Nomenclature to harmonize our language and abbreviations surrounding kidney function has recently been detailed and are summarized in Table 1 12 . Patient‐centered and precise terminology that align with guidelines are preferred and oblige us to move away from the use of the term “renal impairment” to “abnormal kidney function,” as one example.…”

“…These citations include adjustments for body size, unstable S cr , race, and disease conditions, and are by no means a comprehensive list. The jargon surrounding these estimates also leads to their imprecise application and will require action from multiple stakeholders to educate the end user that these estimates are guideposts 12 . The two predominant equations presently in product labels are the Cockcroft‐Gault (C‐G) equation and the modification of diet in kidney disease (MDRD) equation 45 .…”